semaglutide immunogenicity and Follow-On Peptide Therapeutics: Balancing Innovation, Regulation, and Clinical Outcomes Immunogenicity of Generic Peptide Impurities:

This is higher than the general recommendation for tirzepatide users (1.0 to 1.2 g/kg) because of the additive muscle loss risk from autoimmune disease

Fact: What you eat still matters

This is particularly relevant for midlife women, who are often told their fatigue, nausea, or changing body composition is simply part of treatment or part of aging

Compared with controls who did not receive NMV-r, treatment was associated with statistically significant absolute risk reductions in the composite outcome of 2.5% in the CEV1 group, and 1.7% in the CEV2 group

However, the best candidate for Semaglutide is someone with a body-mass index (BMI) of 30 or above or those with a BMI of 27+ and have other health conditions like Type 2 diabetes or high blood pressure